Charles Schwab Investment Management Inc Vertex Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,556,612 shares of VRTX stock, worth $730 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

1,556,612

Previous 1,509,206 3.14%

Holding current value

$730 Million

Previous $614 Million 5.96%

% of portfolio

0.15%

Previous 0.16%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$407.69 - $446.08 $19.3 Million - $21.1 Million	47,406 Added 3.14%	1,556,612 $651 Million
Q4 2023 Feb 06, 2024	BUY	$343.0 - $410.68 $14.3 Million - $17.2 Million	41,778 Added 2.85%	1,509,206 $614 Million
Q3 2023 Nov 08, 2023	BUY	$338.18 - $362.46 $5.94 Million - $6.37 Million	17,564 Added 1.21%	1,467,428 $510 Million
Q2 2023 Aug 09, 2023	BUY	$314.42 - $351.91 $2.12 Million - $2.37 Million	6,727 Added 0.47%	1,449,864 $510 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $7.68 Million - $8.76 Million	27,109 Added 1.91%	1,443,137 $455 Million

Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $8.03 Million - $9.03 Million	28,088 Added 2.02%	1,416,028 $409 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $6.53 Million - $7.29 Million	23,848 Added 1.75%	1,387,940 $402 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $8.61 Million - $10.7 Million	36,626 Added 2.76%	1,364,092 $384 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $14.6 Million - $17.2 Million	65,778 Added 5.21%	1,327,466 $346 Million
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $3.49 Million - $4.4 Million	19,703 Added 1.59%	1,261,688 $277 Million
Q3 2021 Nov 16, 2021	BUY	$181.39 - $202.99 $4.63 Million - $5.19 Million	25,546 Added 2.1%	1,241,985 $225 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $1.88 Million - $2.21 Million	10,014 Added 0.83%	1,216,439 $245 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $11.2 Million - $13.1 Million	-54,152 Reduced 4.3%	1,206,425 $259 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $7.05 Million - $9.4 Million	-34,061 Reduced 2.63%	1,260,577 $298 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $15 Million - $17.8 Million	58,738 Added 4.75%	1,294,638 $352 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $15.9 Million - $20.8 Million	70,386 Added 6.04%	1,235,900 $359 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $7.38 Million - $9.15 Million	36,925 Added 3.27%	1,165,514 $277 Million
Q4 2019 Feb 07, 2020	BUY	$166.71 - $223.91 $3.26 Million - $4.38 Million	19,563 Added 1.76%	1,128,589 $247 Million
Q3 2019 Nov 08, 2019	BUY	$166.23 - $187.09 $6.45 Million - $7.26 Million	38,797 Added 3.63%	1,109,026 $188 Million
Q2 2019 Aug 09, 2019	BUY	$164.61 - $190.37 $2.05 Million - $2.37 Million	12,447 Added 1.18%	1,070,229 $196 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $12.9 Million - $15.4 Million	78,875 Added 8.06%	1,057,782 $195 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $7.06 Million - $8.94 Million	46,494 Added 4.99%	978,907 $162 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $4.23 Million - $4.86 Million	25,205 Added 2.78%	932,413 $180 Million
Q2 2018 Aug 08, 2018	SELL	$145.72 - $169.96 $9.29 Million - $10.8 Million	-63,727 Reduced 6.56%	907,208 $154 Million
Q1 2018 May 07, 2018	BUY	$151.6 - $177.13 $3 Million - $3.5 Million	19,759 Added 2.08%	970,935 $158 Million
Q4 2017 Jan 17, 2018	BUY	$137.28 - $155.55 $3.58 Million - $4.06 Million	26,101 Added 2.82%	951,176 $143 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $137 Million - $150 Million	925,075	925,075 $141 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Vertex Pharmaceuticals Inc Transaction History